Alemtuzamub
Announcement
Collapse
No announcement yet.
Welcome to our forum! Before posting your questions, please read the following terms:
- 1. Forum questions will be responded to by InfantRisk staff as schedules permit during normal business hours.
- 2. This forum is not intended for emergencies or urgent care. For any immediate medical concerns, please seek appropriate medical attention.
- 3. Any statements made by team members should be discussed with your medical care team. Your healthcare providers know you (and your baby) best, and should have a better understanding of your unique situation.
- 4. We are a small team dedicated to helping you as best as we can. However, for the quickest response, we recommend calling the InfantRisk Center at +1(806) 352-2519.
By posting to the forums, you acknowledge and agree to these terms.
The InfantRisk team
Alemtuzamub and bf
Collapse
X
-
Lozwo,
Alemtuzamab is rated an L4-no data-possibly hazardous. No data are available on its transfer to human milk, but it is very unlikely to enter milk, due to its large molecular weight. Some caution is recommended, each woman should understand the benefits and risk of using this type of medication in lactation. The half life is 11 hours (1st dose); 6 days (last dose). I would recommend waiting a week to resume breastfeeding if you are concerned.
The methylprednisonolone is rated an L3-limited data-probably compatible. The amount transferred into breast milk is 0.46-3.15% of your dose. Methylprednisonolone is probably suitable to use during breastfeeding as long as it is taken in low-moderate doses (doses do not exceed 80 mg daily). If high dose pulse therapy is needed (e.g. 1000 mg IV x 3 days), it may be advisable to pump and discard milk for 8-12 hours after each dose.
Sandra Lovato R.N.
InfantRisk Center
806-352-2519
Last edited by admin; 05-24-2016, 11:38 AM.
-
Lozwo,
Vaclovir (Valaciclovir or valacyclovir) is rated an L1-limited data-compatible. The amount transferred into breast milk is 4.7% of your dose. Valacyclovir is rapidly metabolized to acyclovir which transfers to human milk. However, the levels in milk are miniscule compared to the clinical doses administered directly to infants. Acyclovr is quite safe for infants with few reported risks or side effects. The risks to a breastfeeding infant would be minimal. Monitor for vomiting and diarrhea.
As for the alemtuzamab it has a half-life of 6 days after the last dose, it takes approximately 6 half-lives to be completely out so about 36 days to be completely out, but your child is older and not getting as much as milk as a younger infant so a week probably ok.
Sandra Lovato R.N.
InfantRisk Center
806-352-2519
Comment
-
Lozwo,
I just spoke with Dr Hale he thinks it is of no risk after 2 weeks post dose. This medication has a large molecular weight and has poor oral bioavailability. At 2 weeks 75% of the medication is already gone.
Sandra Lovato R.N.
InfantRisk Center
806-352-2519
Comment
Comment